0000899243-19-010278.txt : 20190408 0000899243-19-010278.hdr.sgml : 20190408 20190408194727 ACCESSION NUMBER: 0000899243-19-010278 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190404 FILED AS OF DATE: 20190408 DATE AS OF CHANGE: 20190408 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Jouhikainen Jaakko Taneli CENTRAL INDEX KEY: 0001703641 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-32157 FILM NUMBER: 19738297 MAIL ADDRESS: STREET 1: 900 S CAPITAL OF TEXAS HWY, SUITE 150 CITY: AUSTIN STATE: TX ZIP: 78746 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Savara Inc CENTRAL INDEX KEY: 0001160308 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 841318182 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 900 S. CAPITAL OF TEXAS HIGHWAY STREET 2: SUITE 150 CITY: AUSTIN STATE: TX ZIP: 78746 BUSINESS PHONE: 512-614-1848 MAIL ADDRESS: STREET 1: 900 S. CAPITAL OF TEXAS HIGHWAY STREET 2: SUITE 150 CITY: AUSTIN STATE: TX ZIP: 78746 FORMER COMPANY: FORMER CONFORMED NAME: Mast Therapeutics, Inc. DATE OF NAME CHANGE: 20130312 FORMER COMPANY: FORMER CONFORMED NAME: ADVENTRX PHARMACEUTICALS INC DATE OF NAME CHANGE: 20030613 FORMER COMPANY: FORMER CONFORMED NAME: BIOKEYS PHARMACEUTICALS INC DATE OF NAME CHANGE: 20010928 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-04-04 0 0001160308 Savara Inc SVRA 0001703641 Jouhikainen Jaakko Taneli 6836 BEE CAVE ROAD, BUILDING III SUITE 200 AUSTIN TX 78746 0 1 0 0 President and COO Common Stock 2019-04-04 4 S 0 7815 9.00 D 184754 D Common Stock 2019-04-05 4 S 0 849 9.00 D 183905 D Common Stock 2019-04-08 4 S 0 16336 9.0407 D 167569 D The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 31, 2018. The price is a weighted average sale price. The sale prices ranged from $9.00 to $9.17. The reporting person undertakes to provide Savara Inc., any security holder of Savara Inc., or the staff of the Securities and Exchange Commission, upon receipt of a request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. /s/ David Lowrance, David Lowrance as attorney-in-fact for Jaakko Taneli Jouhikainen 2019-04-08